February 8, 2021
BURLINGTON, Mass. and OXFORD, UK, February 8, 2021 – Blue Earth Diagnostics, a Bracco company…
January 12, 2021
− Clinical utility of Axumin® (fluciclovine F 18) being investigated in expanded areas of cancer…
January 5, 2021
− Expanded oncology portfolio includes comprehensive prostate cancer franchise to address patient management across the…
November 24, 2020
Oxford, UK – 24 November 2020 – Blue Earth Diagnostics, a leading molecular imaging…
October 20, 2020
BURLINGTON, Mass. and OXFORD, UK, October 20, 2020 – Blue Earth Diagnostics, a Bracco…
July 21, 2020
− Patient enrollment now underway in Phase 3 SPOTLIGHT as well as LIGHTHOUSE clinical trials…
June 16, 2020
Oxford, UK, BURLINGTON, Mass., June 16, 2020 – Blue Earth Diagnostics, a Bracco company focused…
May 18, 2020
− Results related to Company’s investigational Phase 3 radiohybrid PSMA agent presented at the AUA2020…
May 1, 2020
Oxford, UK and BURLINGTON, Mass., May 1, 2020 – Blue Earth Diagnostics, a Bracco company focused…
April 21, 2020
Oxford, UK – April 21, 2020 – Blue Earth Diagnostics Ltd, a Bracco company focused on molecular…
March 17, 2020
− Rapid development of research program on investigational Prostate Specific Membrane Antigen-targeted radiohybrid PET imaging…
February 12, 2020
− ASCO 2020 Genitourinary Cancers Symposium and Radiation Oncology Summit: ACRO 2020 − BURLINGTON, Mass.…
